Pirabel during prolonged physical work and recovery — monograph section 6.2
Comparison in people · 2019
- What was studied
- 78 healthy volunteers aged 18–25, divided into eight groups; six-hour physical-load model
- Main finding
- In 78 volunteers, Bemitil 250 mg and Pirabel retained 86.2% and 84.3% of baseline dynamic endurance, versus 68.1% with placebo. Volume II and the 2019 monograph report the same experiment.
Bemitil 250 mg · dynamic and grip endurance · 86.2% and 94% of baseline vs 68.1% and 63% with placebo · Both p<0.05 as marked
Related evidence maps: Sports performance ↗ · Military & occupational ↗
Reported findings and study design
78 healthy volunteers aged 18–25 in eight groups matched on initial performance and cardiorespiratory response. The monograph describes a double-blind six-hour strength-machine circuit, then three hours of recovery.
Population or model 78 healthy volunteers aged 18–25, divided into eight groups; six-hour physical-load model
Dose, route and schedule
The assigned dose was given immediately before the six-hour exercise circuit, four hours after it began and again one hour after it ended for the recovery comparison. Pirabel contained piracetam 600 mg and Bemitil 250 mg per administration. Route was not stated.
Protocol source ↗ · FMBA Volume II, printed pp. 214–219; matches methods in the 2019 monograph
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Bemitil 250 mg · dynamic and grip endurance | 86.2% and 94% of baseline vs 68.1% and 63% with placebo | Both p<0.05 as marked |
| Pirabel · dynamic and grip endurance | 84.3% and 88% of baseline vs 68.1% and 63% with placebo | Both p<0.05 as marked |
| Bemitil 500 mg · dynamic and grip endurance | 72% and 70% of baseline | Only the static endurance comparison is marked significant in this arm. |
| Pirabel · three-hour dynamic recovery index | 1.52 ± 0.17 vs 1.00 ± 0.17 with placebo | p<0.01 as marked |
Table 46 · performance after prolonged work (% of baseline)
| Intervention per administration | PWC₁₇₀ | Dynamic endurance | Static endurance | Grip endurance |
|---|---|---|---|---|
| Placebo | 68 | 68.1 | 23.8 | 63 |
| Bemitil 250 mg | 80* | 86.2* | 32.6 | 94* |
| Bemitil 500 mg | 74 | 72 | 38.2* | 70 |
| Piracetam 600 mg + Bemitil 250 mg | 72 | 84.3* | 34.1 | 88* |
| Amtizol succinate 200 mg | 73 | 72.8 | 38.4* | 65 |
| Yakton 400 mg | 65 | 73.4 | 45.4* | 90 |
| Sydnocarb 10 mg | 61 | 70.9 | 28.6 | 78 |
| Eleutherococcus extract 5 mL | 72 | 87.8* | 32.0 | 68 |
* p<0.05 versus placebo as marked. The narrative and table differ on some contrasts, including Pirabel static endurance.
Table 47 · three-hour recovery indices
| Intervention | Dynamic | Static | Grip | PWC₁₇₀ |
|---|---|---|---|---|
| Placebo | 1.00 ± 0.17 | 0.43 ± 0.09 | 0.90 ± 0.10 | 0.03 ± 0.12 |
| Bemitil 250 mg | 0.99 ± 0.13 | 0.54 ± 0.09 | 1.28 ± 0.17* | 0.52 ± 0.12** |
| Bemitil 500 mg | 1.50 ± 0.29** | 0.53 ± 0.11 | 0.76 ± 0.31 | 0.19 ± 0.25 |
| Pirabel | 1.52 ± 0.17** | 0.31 ± 0.09 | 1.55 ± 0.21** | 0.42 ± 0.26* |
| Amtizol succinate | 1.19 ± 0.44 | 0.50 ± 0.13 | 0.76 ± 0.03 | 0.16 ± 0.26 |
| Yakton | 1.17 ± 0.31 | 0.48 ± 0.13 | 0.72 ± 0.31 | 0.03 ± 0.25 |
| Sydnocarb | 0.96 ± 0.11 | 0.33 ± 0.09 | 0.79 ± 0.06 | 0.24 ± 0.07* |
| Eleutherococcus | 1.12 ± 0.21 | 0.38 ± 0.12 | 0.76 ± 0.31 | 0.19 ± 0.18 |
M ± m as printed. * p<0.05, ** p<0.01 versus placebo.
Both monographs report the same 78-volunteer experiment. Arm sizes and allocation are unresolved. Without a piracetam-only arm, the study cannot establish a combination interaction in humans.
Source for these results ↗ · Reviewed 2026-11-17
Study limitations and source details
Study limitations
- The individual group sizes, allocation and harms were not established.
- No piracetam-only arm was included. The reported results cannot quantify synergy.
Related publications may describe some of the same participants or experiments.
Source details
Recovered monograph section
FMBA Volume II, printed pp. 214–219, Tables 46–47; methods match the 2019 Okovityi, Shustov and Bolotova monograph.
Section 6.2; allocation appraisal incomplete
Sources checked
Citation
S. V. Okovityi, E. B. Shustov, V. Ts. Bolotova. Pirabel during prolonged physical work and recovery — monograph section 6.2 Work Capacity, Fatigue, Correction. Knorus; section 6.2, pp. 184–189
Related compounds
Pirabel
An experimental formulation combining piracetam and Bemitil, studied in Russian fatigue research.
Piracetam
A synthetic compound in the racetam family, also known by the brand Nootropil. It appears in neurological research and historical fatigue-related combination studies.
Bemitil
A synthetic benzimidazole derivative also called bemethyl or Metaprot. Soviet and Russian researchers studied it as an actoprotector, a drug intended to preserve physical work capacity under stress.